

GLP-1's for Weight Management

Member Information				
1.	Last Name:			
3.	rillium ID #: 4. Date of Birth: 5. Gender:			
Pres	ber Information			
1.	Prescriber Name: 2. NPI #:			
3.	equestor Name (Nurse/Office Staff):			
4.	Aailing Address: State: Zip:			
Э.	hone #: Ext Fax #:			
Dru	nformation			
	Prug Name: 2. Strength: 3. Quantity per 30 Days:			
4.	ength of Therapy (in Days): □ up to 30 Days □ 60 Days □ 90 Days □ 120 Days □ 180 Days □ 365 Days □ Other			
Clinical Information				
Ini	Request (Wegovy, Saxenda, and Zepbound):			
1.P	ase list the beneficiary's baseline weight and BMI. Weight Date BMI Date	_		
2. I	he beneficiary 18 years or age or older? 🗆 Yes 🗆 No			
2a. Does the beneficiary have a BMI greater than or equal to 30 kg/m2? ☐ Yes ☐ No				
2	2b. Does the beneficiary have a BMI greater than or equal to 27 kg/m2? ☐ Yes ☐ No			
	2b-i. Does the beneficiary have at least one weight-related comorbidity/risk factor/complication (i.e. hypertension, type 2			
dia	diabetes, obstructive sleep apnea, cardiovascular disease, dyslipidemia)? Yes No List			
3. Is the beneficiary between 12-17 years or age? ☐ Yes ☐ No				
3a. Does the beneficiary have a BMI greater than or equal to the 95th percentile for age and sex? ☐ Yes ☐ No				
	3b. Does the beneficiary have a BMI greater than or equal to 30 kg/m2? ☐ Yes ☐ No			
	3c. Does the beneficiary have a BMI greater than or equal to the 85 th percentile for age and sex? ☐ Yes ☐ No			
	3c-i. Does the beneficiary have at least one weight-related comorbidity/risk factor/complication (i.e. hypertension, type 2			
diabetes, obstructive sleep apnea, cardiovascular disease, dyslipidemia)? Yes No List				
4. Is the beneficiary age 45 years of age or older? Yes No				
4a. Does the beneficiary have a BMI greater than or equal to 27 kg/m2? ☐ Yes ☐ No				
4a-i. Does the beneficiary have established cardiovascular disease (CVD) defined as having a history of myocardial infarction,				
	stroke, or symptomatic peripheral disease? \square Yes \square No List			
5. I	5. Is the beneficiary currently on and will the beneficiary continue lifestyle modification including structured nutrition and physical			
activity, unless physical activity is not clinically appropriate at the time GLP1 therapy commences? Yes No				
6. Will the beneficiary be using the requested agent with another GLP-1? Yes No				
7. Does the beneficiary have any FDA-labeled contraindications to the requested agent, including pregnancy, lactation, history of				
medullary thyroid cancer or multiple endocrine neoplasia type II? Yes No				
Continuation Request (Wegovy, Saxenda, and Zepbound):				
8. Has the beneficiary previously been approved for the requested agent through NC Medicaid's PA process? Yes No				
	neficiary's baseline and current weight. Baseline Wt Date Current Weight Date			
	neficiary's baseline and current BMI. Baseline BMI Date Current BMI Date			
	the beneficiary continuing a current weight loss course of therapy? Yes No			
12. Ages 18 and older - Has the beneficiary lost a total of 5% of pretreatment weight and is maintaining the 5% weight loss?				
☐ Yes ☐ No Baseline Weight Current Weight				
13. Ages (>12 to <18 years) –Has the beneficiary had >4% reduction in baseline BMI and is maintaining the weight loss?				
	Vos D No Passilina Weight Current Weight			

Trillium Health Resources Pharmacy Prior Approval Request for



(Prescriber Signature Mandat			
Signature of Prescriber:	Date:		
o. Onacceptable clinical risk associated with therapedtic change. Please	Слріані.		
6. Unacceptable clinical risk associated with therapeutic change. Please explain:			
reference:			
4. Age specific indications. Please give patient age and explain:5. Unique clinical indication supported by FDA approval or peer reviewed literature. Please explain and provide a general			
provide clinical information:			
3. Clinical contraindication, co-morbidity, or unique patient circumstance as a contraindication to preferred drug(s). Please			
2. Previous episode of an unacceptable side effect or therapeutic failure	e. Please provide clinical information:		
1a. \square Allergic Reaction 1b. \square Drug-to-drug interaction. Please descri	be reaction:		
1. Failed preferred drug(s). List preferred drugs failed:			
Request for Non-Preferred Drug (Saxenda, and Zepbound):			
medullary thyroid cancer or multiple endocrine neoplasia type II? \square Yes \square No			
17. Does the beneficiary have any FDA-labeled contraindications to the requested agent, including pregnancy, lactation, history of			
16. Will the beneficiary be using the requested agent with another GLP-1? \square Yes \square No			
☐ Yes ☐ No			
5. Is the beneficiary currently on and will continue lifestyle modification including structured nutrition and physical activity?			
Rationale			
and the weight loss is maintained, yet the 5% (for adults) and 4% (for adolescents) is not met? \square Yes \square No			
14. Does the beneficiary have a documented weight loss that is deemed to be a significant reduction from BMI per the prescriber			

(Prescriber Signature Mandatory)

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.